To expand the take-home prescribing of methadone through pharmacies.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill provides expansion of methadone for opioid use disorder through prescribing and pharmacies In this subsection: The terms controlled substance, detoxification treatment, dispense, maintenance treatment, and opioid have and requires expansion of methadone for opioid use disorder through prescribing and pharmacies Section 303(h) of the Controlled Substances Act (21 U.S.C. It relies on definition changes, reporting requirements, compliance mandates, and appropriations. The main policy areas are Healthcare Consumers, Healthcare, and Environment.
Who Benefits and How
Public beneficiaries or protected communities affected by the clause could face reduced risk and Patients and health care consumers affected by the bill could gain revenue opportunities.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties, Patients and health care consumers affected by the bill would take on compliance duties, and Environmental and public health interests affected by the bill would take on compliance duties.
Key Provisions
- Provides expansion of methadone for opioid use disorder through prescribing and pharmacies In this subsection: The terms controlled substance, detoxification treatment, dispense, maintenance treatment, and opioid have...
- Requires expansion of methadone for opioid use disorder through prescribing and pharmacies Section 303(h) of the Controlled Substances Act (21 U.S.C.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill provides expansion of methadone for opioid use disorder through prescribing and pharmacies In this subsection: The terms controlled substance, detoxification treatment, dispense, maintenance treatment, and opioid have and requires expansion of methadone for opioid use disorder through prescribing and pharmacies Section 303(h) of the Controlled Substances Act (21 U.S.C.
Key Policy Areas
Healthcare Consumers, Healthcare, Environment
Primary Purpose
The bill provides expansion of methadone for opioid use disorder through prescribing and pharmacies In this subsection: The terms controlled substance, detoxification treatment, dispense, maintenance treatment, and opioid have and requires expansion of methadone for opioid use disorder through prescribing and pharmacies Section 303(h) of the Controlled Substances Act (21 U.S.C.
Policy Domains
Whole bill
Identified Gains
- Public beneficiaries or protected communities affected by the clause
- Patients and health care consumers affected by the bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
- Patients and health care consumers affected by the bill
- Environmental and public health interests affected by the bill
Sponsors
Legislative Progress
IntroducedMr. Markey (for himself, Mr. Paul, Mr. Sanders, Mr. Braun, …
Mr. Markey (for himself, Mr. Paul, Mr. Sanders, Mr. Braun, …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology